Board Member Resigns from DBV Technologies

DBV Technologies, a clinical-stage biopharmaceutical company, has announced the immediate resignation of board member Daniel Soland. Chairman Michel de Rosen expressed gratitude for Soland's contributions, emphasizing his valuable experience and insights since joining in 2015. The company appreciates his role in the Board and the Compensation Committee.

Soland shared his positive experience working with DBV's management and mentioned his anticipation for the continued progress of the VIASKIN® Peanut patch—aimed at treating peanut allergies in children, pending approval.

The Board, reduced to nine members, will collaborate with its Nomination and Governance Committee to appoint a successor, with shareholder ratification anticipated at the next Annual General Meeting.